| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |